Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a Comment »
Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer?
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ipilimumab, TAK-700, tasquinimod, trials | Leave a Comment »
Two drugs already approved in the US that either have been or may be used in the treatment of prostate cancer have now been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, ipilimumab, Xgeva, Yervoy | Leave a Comment »
The U.S. Food & Drug Administration today approved ipilimumab (brand name Yervoy®) for the treatment of patients with metastatic melanoma (an aggressive form of skin cancer).
Filed under: Drugs in development, Management, Treatment | Tagged: ipilimumab, Yervoy | 8 Comments »
Rumors are circulating the the U.S. Food & Drug Administration might approve ipilimumab within the next few days for the treatment of metastatic melanoma. This approval could also offer opportunities for men with some forms of prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: approval, ipilimumab | 1 Comment »
At the Genitourinary Cancers Symposium yesterday afternoon, new data were presented from Phase II studies of tasquinimod and cabozatinib (XL184)
Filed under: Drugs in development, Management | Tagged: cabozatinib, ipilimumab, tasquinimod, XL184 | 1 Comment »
Apparently the U.S. Food & Drug Administration (FDA) has canceled a meeting of the Oncology Drugs Advisory Committee (ODAC) that had been scheduled for February 9. The meeting was originally intended to discuss issues related to a biologics license application for ipilimumab (trade name Yervoy™).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: approval, FDA, ipilimumab | Leave a Comment »
One of the really “hot” pieces of news from ASCO today was the result of a Phase III clinical trial of ipilimumab in a form of metastatic skin cancer called melanoma. This is (perhaps) very important for prostate cancer patients.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, ipilimumab | Leave a Comment »
In June 2009 we reported on data suggesting that the monocolonal antibody ipilimumab appeared to be capable of “downstaging” more advanced forms of prostate cancer such that the patients became re-eligible for localized therapy with curative intent. It’s time for an update based on data presented at the Genitourinary Cancers Symposium last Friday and Saturday.
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, down-stageing, ipilimumab, locallly advanced | Leave a Comment »
According to a report on WebMD, presumably based on media information provided by the Mayo Clinic, two patients with relatively advanced stages of prostate cancer treated with the investigational drug ipilimumab have been put into what appears to be complete remission.
Filed under: Drugs in development, Management, Treatment | Tagged: androgen deprivation therapy, down-staging, ipilimumab, surgery | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site